Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 27

1.

High-resolution assessment of land use impacts on biodiversity in life cycle assessment using species habitat suitability models.

de Baan L, Curran M, Rondinini C, Visconti P, Hellweg S, Koellner T.

Environ Sci Technol. 2015 Feb 17;49(4):2237-44. doi: 10.1021/es504380t. Epub 2015 Jan 28.

PMID:
25584628
2.

Immune checkpoint combinations from mouse to man.

Ai M, Curran MA.

Cancer Immunol Immunother. 2015 Jan 3. [Epub ahead of print]

PMID:
25555570
3.

Is there any empirical support for biodiversity offset policy?

Curran M, Hellweg S, Beck J.

Ecol Appl. 2014 Jun;24(4):617-32. Erratum in: Ecol Appl. 2014 Jul;24(5):1250.

PMID:
24988764
4.

PD-L1 expression in triple-negative breast cancer.

Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, Chawla A, Curran M, Hwu P, Sharma P, Litton JK, Molldrem JJ, Alatrash G.

Cancer Immunol Res. 2014 Apr;2(4):361-70. doi: 10.1158/2326-6066.CIR-13-0127. Epub 2014 Jan 10.

5.

Land use in life cycle assessment: global characterization factors based on regional and global potential species extinction.

de Baan L, Mutel CL, Curran M, Hellweg S, Koellner T.

Environ Sci Technol. 2013 Aug 20;47(16):9281-90. doi: 10.1021/es400592q. Epub 2013 Aug 7.

6.

Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin.

Curran MA, Geiger TL, Montalvo W, Kim M, Reiner SL, Al-Shamkhani A, Sun JC, Allison JP.

J Exp Med. 2013 Apr 8;210(4):743-55. doi: 10.1084/jem.20121190. Epub 2013 Apr 1.

7.

Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model.

Mineharu Y, Muhammad AK, Yagiz K, Candolfi M, Kroeger KM, Xiong W, Puntel M, Liu C, Levy E, Lugo C, Kocharian A, Allison JP, Curran MA, Lowenstein PR, Castro MG.

Neurotherapeutics. 2012 Oct;9(4):827-43. doi: 10.1007/s13311-012-0144-7.

8.

Repertoire enhancement with adoptively transferred female lymphocytes controls the growth of pre-implanted murine prostate cancer.

Jenq RR, Curran MA, Goldberg GL, Liu C, Allison JP, van den Brink MR.

PLoS One. 2012;7(4):e35222. doi: 10.1371/journal.pone.0035222. Epub 2012 Apr 6.

9.

Response to "Ipilimumab (Yervoy) and the TGN1412 catastrophe".

Curran MA, Callahan MK, Subudhi SK, Allison JP.

Immunobiology. 2012 Jun;217(6):590-2. doi: 10.1016/j.imbio.2011.11.001. Epub 2011 Nov 17. No abstract available.

PMID:
22459268
10.

Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production.

Curran MA, Kim M, Montalvo W, Al-Shamkhani A, Allison JP.

PLoS One. 2011 Apr 29;6(4):e19499. doi: 10.1371/journal.pone.0019499.

11.

Toward meaningful end points of biodiversity in life cycle assessment.

Curran M, de Baan L, De Schryver AM, Van Zelm R, Hellweg S, Koellner T, Sonnemann G, Huijbregts MA.

Environ Sci Technol. 2011 Jan 1;45(1):70-9. doi: 10.1021/es101444k. Epub 2010 Nov 3. Review.

PMID:
21047114
12.

The effectiveness of therapeutic ultrasound for musculoskeletal conditions of the lower limb: A literature review.

Shanks P, Curran M, Fletcher P, Thompson R.

Foot (Edinb). 2010 Dec;20(4):133-9. doi: 10.1016/j.foot.2010.09.006. Epub 2010 Oct 18. Review.

PMID:
20961748
13.

A history of prior bare metal stent restenosis is associated with major adverse cardiac events in subsequent bare metal stenting of de novo coronary lesions.

Ferguson MA, Needleman M, Mitchell ES, Carter LI, Bustamante AI, Love KM, Curran MJ.

Cardiology. 2010;116(3):190-3. doi: 10.1159/000319472. Epub 2010 Jul 30.

PMID:
20689275
14.

Vessel reconstruction in acute basilar artery occlusion.

Davis K, Curran M, Lum C.

Can J Neurol Sci. 2010 Jan;37(1):135-7. No abstract available.

PMID:
20169790
15.

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.

Curran MA, Montalvo W, Yagita H, Allison JP.

Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4275-80. doi: 10.1073/pnas.0915174107. Epub 2010 Feb 16.

16.

Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors.

Curran MA, Allison JP.

Cancer Res. 2009 Oct 1;69(19):7747-55. doi: 10.1158/0008-5472.CAN-08-3289. Epub 2009 Sep 8.

17.

Immune rejection of mouse tumors expressing mutated self.

Duan F, Lin Y, Liu C, Engelhorn ME, Cohen AD, Curran M, Sakaguchi S, Merghoub T, Terzulli S, Wolchok JD, Houghton AN.

Cancer Res. 2009 Apr 15;69(8):3545-53. doi: 10.1158/0008-5472.CAN-08-2779. Epub 2009 Apr 7.

18.

Protection of human pancreatic islets using a lentiviral vector expressing two genes: cFLIP and GFP.

Fenjves ES, Ochoa MS, Cechin S, Gay-Rabinstein C, Pérez-Alvarez I, Ichii H, Mendez A, Ricordi C, Curran MA.

Cell Transplant. 2008;17(7):793-802.

PMID:
19044206
19.

Cryptogenic emboli in patients with patent foramen ovale or atrial septal defect associated with the use of nonsteroidal anti-inflammatory drugs.

Ferguson MA, Mackay SM, Ramchandani SR, Thurber JS, Curran MJ, DeGraba TJ.

Cardiology. 2009;113(1):20-4. doi: 10.1159/000164269. Epub 2008 Oct 17.

PMID:
18931493
20.

CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.

Quezada SA, Peggs KS, Curran MA, Allison JP.

J Clin Invest. 2006 Jul;116(7):1935-45. Epub 2006 Jun 15.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk